News & Industry Bulletins

Monday, January 12, 2015

Dominion Diagnostics takes key role in 2015 National Conference on Addiction Disorders

Addiction Professional and Behavioral Healthcare today announced that Dominion Diagnostics is the Title Sponsor of the 2015 National Conference on Addiction Disorders and Behavioral Healthcare Executive Summit, taking place August 1 to 4, 2015, in St. Louis.

Monday, January 5, 2015

Aurora Diagnostics Announces Sale of Greensboro, N.C., Blood Testing Laboratory to Dominion Diagnostics

Aurora Diagnostics, the leading independent specialized laboratory company focused on anatomic pathology, announced today that it has sold its Greensboro, N.C., blood testing clinical laboratory to Dominion Diagnostics, effective December 31, 2014.

Friday, December 5, 2014

Heroin Drug Overdoses Nearly Tripled From 1999 to 2012: CDC

Overdose deaths involving heroin nearly tripled from 1999 to 2012, a new government report concludes. Overall, drug overdose deaths more than doubled. The Centers for Disease Control and Prevention (CDC) found drug overdose deaths rose from 6.1 per 100,000 population in 1999 to 13.1 in 2012. Between 2011 and 2012, the rate of drug-poisoning deaths involving heroin increased 35 percent, from 1.4 per 100,000 to 1.9.

Tuesday, December 2, 2014

Massachusetts General Hospital & Harvard Medical School's Recovery Research Institute (RRI) features findings from recently published research on CARD®, developed by Dominion Diagnostics

The Recovery Research Institute (RRI) at the Massachusetts General Hospital and Harvard Medical School is currently featuring the recently published CARD® research study Systematic Evaluation of “Compliance” to Prescribed Treatment Medications and “Abstinence” from Psychoactive Drug Abuse in Chemical Dependence Programs: Data from the Comprehensive Analysis of Reported Drugs in its monthly newsletter.

Wednesday, November 26, 2014

FDA approves extended-release, single-entity hydrocodone product with abuse deterrent properties

The U.S. Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Hysingla ER has approved labeling describing the product’s abuse-deterrent properties consistent with the FDA’s 2013 draft guidance for industry, Abuse-Deterrent Opioids – Evaluation and Labeling.

Thursday, October 30, 2014

Study Finds Positive Drug Test from Secondhand Marijuana Smoke Unlikely

A new study finds it is unlikely that a person exposed to secondhand marijuana smoke will test positive for marijuana themselves. While it is possible that extreme marijuana smoke exposure could produce a positive urine test, this occurrence is likely to be rare and limited to the hours immediately after exposure, according to researchers from Johns Hopkins University.

Thursday, October 16, 2014

Medical Groups: Pregnant Women Should Be Asked About Drug Use

Several medical groups are calling for verbal drug screening for pregnant women, followed by a urine test if necessary, USA Today reports. The recommendation is meant to reduce the growing number of babies born with neonatal abstinence syndrome (NAS).

Tuesday, October 14, 2014

Leading Medication Monitoring Coalition Announces Election of Robert Garvey to Serve as New Chairman

The Coalition for Excellence in Medication Monitoring (CEMM) – the leading voice of the medication monitoring clinical laboratory industry – has elected Robert Garvey, CEO of Dominion Diagnostics, to serve as its new Chairman.

Tuesday, September 30, 2014

Dominion Diagnostics Now Offers Detection of "Z-Drugs" Commonly Prescribed for Insomnia

Dominion Diagnostics, a leading national provider of drug testing, medication monitoring, and actionable clinical information, now offers a new laboratory‐based urine test for the detection of commonly prescribed Z‐Drugs.

Tuesday, September 23, 2014

Improvement of Abstinence in Chemical Dependence Treatment Programs with Comprehensive Analysis of Reported Drugs (CARD)®

Scientists in the open access journal PLOSONE reported today on a comprehensive systematic evaluation of compliance to prescribed treatment medications and abstinence from psychoactive drug abuse in chemical dependence programs.